◩ SEQ2STUDY / RESEARCH REPORTDEMONSTRATION · UNVALIDATED
INTEGRATED PRECLINICAL CHARACTERIZATIONCandidate readiness
assessment.
Project S2S-DEMO-024 · Sample format: VHH / nanobody · Three simulated candidates
01 / Executive scientific perspective
Based on the illustrative dataset below, AB-01 would be prioritized for confirmation and appropriate next-step feasibility work. AB-02 has stronger illustrative binding but a substantially higher aggregation liability; further engineering or formulation exploration would be recommended before advancing.
02 / Candidate overview
| Readout | AB-01 | AB-02 | AB-03 |
|---|---|---|---|
| Example Kd (SPR) | 8.4 nM | 1.7 nM | 37 nM |
| Example expression yield | 22 mg/L | 8 mg/L | 17 mg/L |
| Example SEC monomer | 98.3% | 89.6% | 96.8% |
| Example thermal Tm | 67.2°C | 63.1°C | 71.0°C |
| Illustrative conclusion | Prioritize | Optimize | Review |
03 / Analytical evidence
A final client report could include raw chromatograms, SEC integration, kinetic sensorgrams with binding model and fitting residuals, concentration-dependent thermal profiles, repeatability and batch metadata. Specific tests, controls and quality thresholds would be defined in the signed study plan.
04 / Risk matrix
| Domain | Illustrative concern | Suggested action |
|---|---|---|
| Expression | AB-02 demonstrates lower recovery | Assess expression format and yield reproducibility |
| Binding | Affinity rank may be assay-context-dependent | Repeat with orthogonal controls where needed |
| Aggregation | AB-02 elevated HMW content | Repeat SEC and consider stress / concentration study |
| In vivo readiness | Study-specific requirements unresolved | Align species cross-reactivity and material QC with protocol |
05 / Scope & limitations
These early characterizations support research-stage candidate prioritization only. They cannot establish clinical safety, developability across all conditions, efficacy, regulatory acceptability, GMP quality, GLP compliance or suitability for a given animal experiment without study-specific evaluation.
CONFIDENTIAL REPORT STYLE · DEMONSTRATION ONLY01 / 12 (EXAMPLE)